Neoadjuvant endocrine therapy with exemestane followed by response‐guided combination therapy with low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study

Abstract Patients with estrogen receptor (ER)‐positive breast cancer are less likely to achieve a pathological complete response (pCR) with neoadjuvant chemotherapy. Neoadjuvant endocrine therapy may be more appropriate than neoadjuvant chemotherapy in these hormone‐sensitive patients. Most patients...

Descrición completa

Detalles Bibliográficos

Principais autores:	Nobuaki Sato, Norikazu Masuda, Takashi Morimoto, Takayuki Ueno, Chizuko Kanbayashi, Koji Kaneko, Hiroyuki Yasojima, Shigehira Saji, Hironobu Sasano, Satoshi Morita, Shinji Ohno, Masakazu Toi
Formato:	Artigo
Idioma:	Inglês
Publicado:	Wiley 2018-07-01
Series:	Cancer Medicine
Assuntos:	aromatase inhibitors breast neoplasms Ki67 index neoadjuvant therapy postmenopause tailored therapy
Acceso en liña:	https://doi.org/10.1002/cam4.1600
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!